دورية أكاديمية

Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers

التفاصيل البيبلوغرافية
العنوان: Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers
المؤلفون: Nho, Kwangsik, Kueider-Paisley, Alexandra, Ahmad, Shahzad, MahmoudianDehkordi, Siamak, Arnold, Matthias, Risacher, Shannon L., Louie, Gregory, Blach, Colette, Baillie, Rebecca, Han, Xianlin, Kastenmüller, Gabi, Trojanowski, John Q., Shaw, Leslie M., Weiner, Michael W., Doraiswamy, P. Murali, van Duijn, Cornelia, Saykin, Andrew J., Kaddurah-Daouk, Rima, Meikle, Peter, Alzheimer's Disease Neuroimaging Initiative, Alzheimer Disease Metabolomics Consortium
المصدر: JAMA Network Open, 2(7), Art. No. e197978, (2019-07-31)
بيانات النشر: American Medical Association
سنة النشر: 2019
المجموعة: Caltech Authors (California Institute of Technology)
الوصف: Importance Increasing evidence suggests an important role of liver function in the pathophysiology of Alzheimer disease (AD). The liver is a major metabolic hub; therefore, investigating the association of liver function with AD, cognition, neuroimaging, and CSF biomarkers would improve the understanding of the role of metabolic dysfunction in AD. Objective To examine whether liver function markers are associated with cognitive dysfunction and the "A/T/N" (amyloid, tau, and neurodegeneration) biomarkers for AD. Design, Setting, and Participants In this cohort study, serum-based liver function markers were measured from September 1, 2005, to August 31, 2013, in 1581 AD Neuroimaging Initiative participants along with cognitive measures, cerebrospinal fluid (CSF) biomarkers, brain atrophy, brain glucose metabolism, and amyloid-β accumulation. Associations of liver function markers with AD-associated clinical and A/T/N biomarkers were assessed using generalized linear models adjusted for confounding variables and multiple comparisons. Statistical analysis was performed from November 1, 2017, to February 28, 2019. Exposures Five serum-based liver function markers (total bilirubin, albumin, alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase) from AD Neuroimaging Initiative participants were used as exposure variables. Main Outcomes and Measures Primary outcomes included diagnosis of AD, composite scores for executive functioning and memory, CSF biomarkers, atrophy measured by magnetic resonance imaging, brain glucose metabolism measured by fludeoxyglucose F 18 (¹â¸F) positron emission tomography, and amyloid-β accumulation measured by [¹â¸F]florbetapir positron emission tomography. Results Participants in the AD Neuroimaging Initiative (n = 1581; 697 women and 884 men; mean [SD] age, 73.4 [7.2] years) included 407 cognitively normal older adults, 20 with significant memory concern, 298 with early mild cognitive impairment, 544 with late mild cognitive impairment, and 312 with AD. An ...
نوع الوثيقة: article in journal/newspaper
اللغة: unknown
العلاقة: https://doi.org/10.1001/jamanetworkopen.2019.7978Test; oai:authors.library.caltech.edu:38j37-20095; https://www.ncbi.nlm.nih.gov/pmc/PMC6669786Test; eprintid:101616; resolverid:CaltechAUTHORS:20200227-105117493
DOI: 10.1001/jamanetworkopen.2019.7978
الإتاحة: https://doi.org/10.1001/jamanetworkopen.2019.7978Test
https://www.ncbi.nlm.nih.gov/pmc/PMC6669786Test
حقوق: info:eu-repo/semantics/openAccess ; Other
رقم الانضمام: edsbas.40FED491
قاعدة البيانات: BASE